Larimar Therapeutics (LRMR) Accounts Payables (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Accounts Payables for 14 consecutive years, with $7.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 82.23% year-over-year to $7.6 million; the trailing twelve-month figure through Jun 2026 stood at $7.6 million (up 82.23% YoY), and the FY2025 full-year result was $5.2 million, up 115.18% from the prior year.
• Accounts Payables advanced to $7.6 million in Q2 2026 per LRMR's latest filing, from $5.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.1 million in Q3 2025 and bottomed at $425000.0 in Q2 2022.
• Historically, Accounts Payables has averaged $2.9 million across 5 years, with a median of $2.3 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables slumped 71.25% in 2023, then jumped 558.36% in 2025.
• Over 5 years, Accounts Payables stood at $1.7 million in 2022, then fell by 23.9% to $1.3 million in 2023, then soared by 88.93% to $2.4 million in 2024, then surged by 115.18% to $5.2 million in 2025, then jumped by 45.65% to $7.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $7.6 million, $5.2 million, and $11.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.